Ractigen Therapeutics Reports the First Patient Dosing with RAG-17 in P-I Study to Treat Amyotrophic Lateral Sclerosis (ALS)
Shots:
- Ractigen dosed the first patient with RAG-17 under the P-I clinical evaluation for treating SOD1 gene mutated Amyotrophic Lateral Sclerosis (ALS)
- The P-I study will assess safety, tolerability, PK/PD & preliminary efficacy of RAG-17 for the treatment of ALS with SOD1 gene mutation
- RAG-17 (delivered via SCAD platform) is a siRNA that targets SOD1 gene in ALS patients with pathogenic mutations. Its preclinical studies, incl. hSOD1G93A mouse model, showed strong therapeutic efficacy in improving motor function & survival, while IIT results depicted favorable safety & tolerability with mild AEs
Ref: Ractigen Therapeutics | Image: Ractigen Therapeutics
Related News:- Ractigen Therapeutics’ RAG-18 Gains the US FDA’s Orphan Drug Designation to Treat DMD and BMD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
